Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BBIO 
BridgeBio Pharma Inc (BBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BBIO (3-star) is a STRONG-BUY. BUY since 85 days. Profits (44.34%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $62.43
1 Year Target Price $62.43
| 10 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 66.03% | Avg. Invested days 34 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.05B USD | Price to earnings Ratio - | 1Y Target Price 62.43 |
Price to earnings Ratio - | 1Y Target Price 62.43 | ||
Volume (30-day avg) 19 | Beta 1.23 | 52 Weeks Range 21.72 - 52.84 | Updated Date 08/28/2025 |
52 Weeks Range 21.72 - 52.84 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.75 | Actual -0.95 |
Profitability
Profit Margin - | Operating Margin (TTM) -120.72% |
Management Effectiveness
Return on Assets (TTM) -41.96% | Return on Equity (TTM) -1789.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10581520113 | Price to Sales(TTM) 42.62 |
Enterprise Value 10581520113 | Price to Sales(TTM) 42.62 | ||
Enterprise Value to Revenue 44.87 | Enterprise Value to EBITDA -9.4 | Shares Outstanding 191168992 | Shares Floating 151275461 |
Shares Outstanding 191168992 | Shares Floating 151275461 | ||
Percent Insiders 4.77 | Percent Institutions 101.37 |
Upturn AI SWOT
BridgeBio Pharma Inc
Company Overview
History and Background
BridgeBio Pharma, Inc. was founded in 2015. It focuses on discovering, developing, and delivering transformative medicines for genetic diseases and cancers with clear genetic drivers.
Core Business Areas
- Drug Development: Focuses on developing novel therapeutics for genetic diseases and cancers.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Commercialization: Commercializes approved therapies to bring them to market.
Leadership and Structure
Neil Kumar serves as the CEO. The organizational structure includes departments dedicated to research and development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- NULIBRY (fosdenopterin): NULIBRY is approved for the treatment of molybdenum cofactor deficiency (MoCD) Type A. Market share data is difficult to ascertain exactly, but Nulibry is the only FDA approved treatment of MoCD Type A. Competitors include companies developing therapies for similar rare diseases, such as Ultragenyx Pharmaceutical.
- TRUSELTIQ (infigratinib): TRUSELTIQ is approved for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement. Market share data is not readily available. Competitors in this area include companies with oncology drugs, such as QED Therapeutics.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. It is rapidly evolving with advances in genomics and personalized medicine.
Positioning
BridgeBio positions itself as a leader in targeting genetic diseases and cancers with clear genetic drivers, using a portfolio approach to mitigate risk.
Total Addressable Market (TAM)
The TAM for genetic diseases and cancers is substantial, estimated to be hundreds of billions of dollars. BridgeBio is positioning itself to address niche markets within this larger TAM, focusing on areas where it can deliver significant clinical benefit.
Upturn SWOT Analysis
Strengths
- Focus on genetically driven diseases
- Strong pipeline of drug candidates
- Experienced management team
- Strategic partnerships
Weaknesses
- High R&D costs
- Dependence on clinical trial success
- Limited number of commercially available products
- Potential regulatory hurdles
Opportunities
- Expansion of pipeline through acquisitions and collaborations
- Potential for breakthrough therapies in underserved markets
- Increasing demand for personalized medicine
- Advancements in genetic research
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from larger pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- LLY
- VRTX
- AMGN
- GILD
Competitive Landscape
BridgeBio is focused on niche markets within the broader biopharmaceutical landscape, giving them an advantage in genetic diseases. However they face competition from larger, more established companies with greater resources.
Major Acquisitions
Phoenix Tissue Repair
- Year: 2019
- Acquisition Price (USD millions): 97
- Strategic Rationale: Expanded BridgeBiou2019s pipeline into recessive dystrophic epidermolysis bullosa (RDEB).
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by the advancement of drug candidates through clinical trials and subsequent approvals.
Future Projections: Future growth depends on the success of pipeline products, expansion into new indications, and strategic collaborations.
Recent Initiatives: Recent initiatives include focusing on key clinical trials, securing regulatory approvals for new therapies, and expanding partnerships.
Summary
BridgeBio Pharma focuses on genetic diseases and cancers with promising therapies. Success hinges on R&D and clinical trials. It needs to carefully manage competition and adapt to regulatory hurdles, yet the company has strong growth potential within specific market areas.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
- Financial News Outlets
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary. Financial data is based on publicly available information and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BridgeBio Pharma Inc
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2019-06-27 | Co-Founder, CEO & Director Dr. Neil Kumar Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 725 | Website https://bridgebio.com |
Full time employees 725 | Website https://bridgebio.com | ||
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.